COVID-19 lockdown may have led to waning immunity to gastrointestinal viruses

Following the first stay-at-home orders issued in the U.S. to curb the spread of COVID-19, gastrointestinal viruses such as norovirus, rotavirus and adenovirus all but disappeared from California communities, and remained at very low levels for nearly 2 years.

HF-158K1 by HighField Biopharmaceuticals for Gastric Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Gastric Cancer.

July 6, 2024

New £3 million research unit seeks to tackle dementia

Funded by a £3 million grant from The National Institute for Health and Care Research (NIHR), the DeNPRU will produce research on prevention, diagnosis and

August 1, 2023

HistoSonics Raises $102M for Liver Tumor Treatment

What You Should Know: – HistoSonics, a medical technology company specializing in histotripsy, a non-invasive treatment for liver tumors raises $102M in Series D financing

August 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.